Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

NCT07150845 | Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: EVO756-AD001
• Study Type: interventional
• Target: 120
• Locations: 2 countries
• Sites: 29

Brief Summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Conditions

Atoptic Dermatitis

Keywords

atopic dermatitis; eczema; itch

Outcome Measures

Primary Outcomes (1)

• Percentage change in Eczema Area and Severity Index (EASI) from Baseline

  Week 12

Secondary Outcomes (9)

• Percentage change in EASI from Baseline

  Weeks 2, 4, and 8

• Mean changes in EASI from Baseline

  Week 2, 4, 8, and 12

• Proportion of subjects with EASI-50, EASI-75, and EASI-90 from Baseline

  Weeks 2, 4, 8, and 12

• Mean and absolute changes in validated Investigator Global Assessment (vIGA) score from Baseline

  Weeks 2, 4, 8, and 12

• Proportion of subjects achieving a vIGA score of 0,1 with at least a 2-point reduction from Baseline

  Weeks 2, 4, 8, and 12

Study Arms (4)

Dose 1

EXPERIMENTAL

Orally administered EVO756, Dose 1

Drug: EVO756

Dose 2

EXPERIMENTAL

Orally administered EVO756, Dose 2

Drug: EVO756

Dose 3

EXPERIMENTAL

Orally administered EVO756, Dose 3

Drug: EVO756

Placebo

PLACEBO COMPARATOR

Placebo control

Drug: Placebo control

Interventions

EVO756 DRUG

Dose 1

Dose 1

Placebo control DRUG

Placebo control

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Chronic AD that has been present for ≥6 months
• Validated-Investigator's Global Assessment score of ≥3
• EASI of ≥16
• BSA of AD involvement of ≥10%

You may not qualify if:

• Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
• Use of certain medications
• Presence of skin comorbidities or other condition(s) that may interfere with study assessments
• Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Sponsors & Collaborators

• Evommune, Inc.: lead

Study Sites (29)

Saguaro Dermatology

Phoenix, Arizona, 85008, United States

RECRUITING

Center for Dermatology Clinical Research

Fremont, California, 94538, United States

RECRUITING

Metropolis Dermatology - Downtown Los Angeles

Los Angeles, California, 90017, United States

RECRUITING

Skin and Beauty Center

Pasadena, California, 91105, United States

RECRUITING

Skin Care Research, LLC

Boca Raton, Florida, 33486, United States

RECRUITING

Driven Research, LLC

Coral Gables, Florida, 33134, United States

RECRUITING

Skin Care Research - Hollywood Dermatology

Hollywood, Florida, 33021, United States

RECRUITING

TrueBlue Clinical Research

Tampa, Florida, 33609, United States

RECRUITING

DS Research

Clarksville, Indiana, 47129, United States

RECRUITING

Equity Medical

Bowling Green, Kentucky, 42104, United States

RECRUITING

Aesthetic and Dermatology Center

Rockville, Maryland, 20850, United States

RECRUITING

Great Lakes Research Group, Inc.

Bay City, Michigan, 48706, United States

RECRUITING

Revival Research Institute, LLC

Troy, Michigan, 48084, United States

RECRUITING

Michigan Dermatology Institute

Waterford, Michigan, 48328, United States

RECRUITING

MediSearch Clinical Trials

Saint Joseph, Missouri, 64507, United States

RECRUITING

Empire Dermatology

East Syracuse, New York, 13057, United States

RECRUITING

Equity Medical

New York, New York, 10023, United States

RECRUITING

Skin Search of Rochester, Inc.

Rochester, New York, 14623, United States

RECRUITING

Wilmington Dermatology Center

Wilmington, North Carolina, 28405, United States

RECRUITING

DOCS Dermatology Clinical Research

Canal Winchester, Ohio, 43110, United States

RECRUITING

International Clinical Research - Murfreesboro

Murfreesboro, Tennessee, 37130, United States

RECRUITING

Stryde Research

Lewisville, Texas, 75056, United States

RECRUITING

Progressive Clinical Research

San Antonio, Texas, 78213, United States

RECRUITING

Jordan Valley Dermatology Center

South Jordan, Utah, 84095, United States

RECRUITING

Pacific Clinical Research Network (PCRN) - Christchurch

Christchurch Central City, Christchurch, 8013, New Zealand

RECRUITING

Optimal Clinical Trials

Auckland, NZL, 1010, New Zealand

RECRUITING

Optimal Clinical Trials

Auckland, NZL, 632, New Zealand

RECRUITING

Clinical Trials NZ Limited

Hamilton, NZL, 3204, New Zealand

RECRUITING

Momentum Clinical Research Lower Hutt

Lower Hutt, NZL, 5010, New Zealand

RECRUITING

MeSH Terms

Conditions

Dermatitis, Atopic; Eczema; Pruritus

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Jill Abbey, MBA

CONTACT

925-286-0832; jill.abbey@evommune.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2025
• First Posted: September 2, 2025
• Study Start: August 26, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: April 24, 2026

Record last verified: 2025-10

Locations

NZ (5); US (24)